Pointe-Claire, Canada

Stéphane Dorich

USPTO Granted Patents = 13 

Average Co-Inventor Count = 1.6

ph-index = 3

Forward Citations = 28(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
13 patents (USPTO):Explore Patents

Title: Stéphane Dorich: Innovator in Pyridazine Compounds

Introduction

Stéphane Dorich is a notable inventor based in Pointe-Claire, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific proteins involved in various diseases. With a total of 13 patents to his name, Dorich's work is recognized for its potential impact on medical treatments.

Latest Patents

One of Stéphane Dorich's latest patents involves pyridazine compounds designed for inhibiting NLRP3. This patent outlines the use of inhibitors of NLRP3, which are useful in treating diseases and disorders associated with this protein. The formula presented in the patent showcases the innovative approach Dorich has taken in addressing complex health issues.

Career Highlights

Throughout his career, Stéphane Dorich has worked with several prominent companies in the biotechnology sector. Notably, he has been associated with Ventus Therapeutics U.S., Inc. and Repare Therapeutics Inc. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research.

Collaborations

Stéphane Dorich has collaborated with talented individuals in his field, including Stéphane Ciblat and Amandine Chefson. These partnerships have fostered an environment of innovation and creativity, leading to advancements in their shared research interests.

Conclusion

Stéphane Dorich is a distinguished inventor whose work in pyridazine compounds has the potential to revolutionize treatments for various diseases. His contributions to the field, along with his collaborations, highlight the importance of innovation in medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…